Updates in Thyroid Cancer

Selpercatinib Earns Full FDA Approval Status in RET+ Thyroid Cancer
Data from the phase 1/2 LIBRETTO-001 trial support the FDA approval of selpercatinib in patients with RET fusion-positive thyroid cancer.
Read More

ASTRO Updates Guidelines for Radiation Therapy in HPV-Associated OPSCC
As the practice of radiation therapy evolves in HPV-associated OPSCC, updated evidence-based ASTRO guidelines may help inform clinical practices.
Read More